The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
CD39 and CD73 in immunity and inflammation
Open accessAbstract
The enzymatic activities of CD39 and CD73 play strategic roles in calibrating the duration, magnitude, and chemical nature of purinergic signals delivered to immune cells through the conversion of ADP/ATP to AMP and AMP to adenosine, respectively. This drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. The CD39/CD73 pathway changes dynamically with the pathophysiological context in which it is embedded. It is becoming increasingly appreciated that altering this catabolic machinery can change the course or dictate the outcome of several pathophysiological events, such as AIDS, autoimmune diseases, infections, atherosclerosis, ischemia-reperfusion injury, and cancer, suggesting these ecto-enzymes are novel therapeutic targets for managing a variety of disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hart, M. L., Grenz, A., Gorzolla, I. C., Schittenhelm, J., Dalton, J. H., & Eltzschig, H. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903617 · Cited by 132
RetractedVignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217
Self-citationYegutkin, G. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.024 · Cited by 1,154
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Self-citationATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors
Chen, Y., Corriden, R., Inoue, Y., Yip, L., Hashiguchi, N., Zinkernagel, A., Nizet, V., Insel, P. A., & Junger, W. G. (2006) · Science · doi:10.1126/science.1132559 · Cited by 858
Immune cell regulation by autocrine purinergic signalling
Junger, W. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri2938 · Cited by 810
Cited by
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Self-citationIntegrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.007 · Cited by 730
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632
The Coming Decade of Cell Death Research: Five Riddles
Green, D. R. (2019) · Cell · doi:10.1016/j.cell.2019.04.024 · Cited by 566
Joshi, N. S., Akama-Garren, E. H., Lu, Y., Lee, D.-Y., Chang, G. P., Li, A., DuPage, M., Tammela, T., Kerper, N. R., Farago, A. F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.006 · Cited by 520
Zheng, L., Kelly, C. J., & Colgan, S. P. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00191.2015 · Cited by 499
Damage-associated molecular patterns in cancer: a double-edged sword
Hernandez, C., Huebener, P., & Schwabe, R. F. (2016) · Oncogene · doi:10.1038/onc.2016.104 · Cited by 480
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Nucleotide metabolism: a pan-cancer metabolic dependency
Mullen, N. J., & Singh, P. K. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00557-7 · Cited by 466
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448
Principles of regulatory T cell function
Dikiy, S., & Rudensky, A. Y. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.004 · Cited by 445
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells
Canale, F. P., Ramello, M. C., Núñez, N., Furlan, C. L. A., Bossio, S. N., Serrán, M. G., Boari, J. T., del Castillo, A., Ledesma, M., Sedlik, C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-16-2684 · Cited by 408
CD39/CD73/A2AR pathway and cancer immunotherapy
Xia, C., Yin, S., To, K. K. W., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01733-x · Cited by 399
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
Goswami, S., Walle, T., Cornish, A. E., Basu, S., Anandhan, S., Fernandez, I., Vence, L., Blando, J., Zhao, H., Yadav, S. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0694-x · Cited by 356
Plasma metabolomic and lipidomic alterations associated with COVID-19
Wu, D., Shu, T., Yang, X., Song, J.-X., Zhang, M., Yao, C., Liu, W., Huang, M., Yu, Y., Yang, Q., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa086 · Cited by 361
Roederer, M., Quaye, L., Mangino, M., Beddall, M. H., Mahnke, Y., Chattopadhyay, P., Tosi, I., Napolitano, L., Terranova Barberio, M., Menni, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.046 · Cited by 296
Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD
Haarhaus, M., Brandenburg, V., Kalantar-Zadeh, K., Stenvinkel, P., & Magnusson, P. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.60 · Cited by 316
Purinergic signalling and immune cells
Burnstock, G., & Boeynaems, J.-M. (2014) · Purinergic Signalling · doi:10.1007/s11302-014-9427-2 · Cited by 309
Yegutkin, G. G. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.953627 · Cited by 299
Targeting CD73 in the tumor microenvironment with MEDI9447
Hay, C. M., Sult, E., Huang, Q., Mulgrew, K., Fuhrmann, S. R., McGlinchey, K. A., Hammond, S. A., Rothstein, R., Rios-Doria, J., Poon, E., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1208875 · Cited by 287
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
Horenstein, A. L., Chillemi, A., Zaccarello, G., Bruzzone, S., Quarona, V., Zito, A., Serra, S., & Malavasi, F. (2013) · OncoImmunology · doi:10.4161/onci.26246 · Cited by 279
Telesford, K. M., Yan, W., Ochoa-Reparaz, J., Pant, A., Kircher, C., Christy, M. A., Begum-Haque, S., Kasper, D. L., & Kasper, L. H. (2015) · Gut Microbes · doi:10.1080/19490976.2015.1056973 · Cited by 252
“CD39 along with CD73 are part of a sensitive purigenic signaling network by which extracellular nucleotides are detected and degraded in the pericellular environment thereby influencing immune responses.(28) Aside from direct contributions to suppression via generation of adenosine, CD39 may function to prolong Treg l…”
BackgroundSitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215
He, B., Hoang, T. K., Wang, T., Ferris, M., Taylor, C. M., Tian, X., Luo, M., Tran, D. Q., Zhou, J., Tatevian, N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160961 · Cited by 196
“the therapeutic effect of inosine on t reg cell–deficient SF mice is mediated by A2A receptors T reg cells control Th1/Th2 mediated by A2A receptors (Deaglio et al., 2007; Csóka et al., 2008; Antonioli et al., 2013).”
BackgroundInfluentialThe role of p2x7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases
Coutinho-Silva, R., Morandini, A., & Savio, L. B. (2014) · Biomedical Journal · doi:10.4103/2319-4170.127803 · Cited by 81
“Regarding this, several studies have demonstrated the importance of ecto‐5′‐nucleotidase/ CD73 in generating an adenosine‐rich environment in inflammation and infection, as detailed further in several recent reviews.([62,70,103])”
BackgroundResultT-Cell Aging-Associated Phenotypes in Autoimmune Disease
Zhao, T. V., Sato, Y., Goronzy, J. J., & Weyand, C. M. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.867950 · Cited by 50
Immunotherapy Resistance in Glioblastoma
Wang, E. J., Chen, J.-S., Jain, S., Morshed, R. A., Haddad, A. F., Gill, S., Beniwal, A. S., & Aghi, M. K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750675 · Cited by 34
Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients
Pietrobon, A. J., Andrejew, R., Custódio, R. W. A., Oliveira, L. D. M., Scholl, J. N., Teixeira, F. M. E., de Brito, C. A., Glaser, T., Kazmierski, J., Goffinet, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012027 · Cited by 23
“ATP dephosphorylation into ADO mediated by ectonucleotidases is a key regulatory mechanism of immune responses, promoting the shift from ATP-driven inflammation to immunosuppression induced by ADO (41).”
BackgroundJin, H., Zhong, X., Zhang, C., Wu, Y., Sun, J., Wang, X., Wang, Z., Zhu, J., Jiang, Y., Du, X., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102131 · Cited by 2
“The expression of CD39 and CD73, and their catabolic ability to secrete adenosine are also related to M1/M2 differentiation and cytokine production in monocytes [40].”
Metadata
- Authors
- Antonioli, L., Pacher, P., Vizi, E. S., & Haskó, G.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 19
- Issue
- 6
- Pages
- 355-367
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2086556660
- Cited by
- 1,263
- References
- 165
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.